Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 35 of 35 results for acute lymphoblastic leukaemia

  1. KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]

    Discontinued Reference number: GID-TA10316

    Technology appraisal guidance
    Discontinued

  2. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (TA554)

    This guidance has been updated and replaced by NICE technology appraisal guidance 975.  

    Technology appraisal guidance
    Published
    21 December 2018

  3. New option for adult leukaemia patients as we recommend treatment

    Today we've recommended an immunotherapy treatment that could prevent blood cancer from returning in adults who've responded well to initial therapy.

    News
    Last updated
    21 February 2025

  4. NICE recommended personalised immunotherapy to treat blood cancer in children and young adults to be made routinely available on the NHS

    Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.

    News
    Last updated
    12 April 2024

  5. Two new personalised immunotherapy treatments for aggressive forms of blood cancer recommended for the Cancer Drugs Fund

    NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood cancer.

    News
    Last updated
    13 June 2024